Heart, Lung and Circulation

Slides:

Advertisements

Similar presentations

Atrial Fibrillation Stroke Prevention with Oral Anticoagulants Why is there discordance between guideline committees & specialists when the data is based.

Advertisements

Adam M. Levine, DO, FACC Clinical Assistant Professor of Medicine Rowan University September 12 th, 2015.

Palpitations & Atrial Fibrillation Dr Mehul B Dhinoja, Consultant Cardiologist & Electrophysiologist BMI The London Independent Hospital.

Clinical pathway for people with atrial fibrillation or at risk of atrial fibrillation Dr Ruth Chambers OBE LTC Priority Lead, West Midlands Academic Health.

Atrial Fibrillation and Heart Failure Andrew A. Grace, MB, PhD, FRCP Heart Failure Clinics Volume 9, Issue 4, (October 2013) DOI: /j.hfc

Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. Benefit of Anticoagulation Unlikely in Patients With Atrial.

Pulmonary Vein Isolation Compared to Rate Control in Patients with Atrial Fibrillation: A Systematic Review and Meta-analysis Kaivan Vaidya, MBBS, Clare.

Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart DiseaseClinical Perspective by Michael D. Ezekowitz, Rangadham.

How to Navigate the New Oral Anticoagulants and Deal With Triple Therapy Dr. Morteza Safi Professor of interventional cardiology Cardiovascular Research.

Length of Hospital Stay for Bleeding Among Adults with Atrial Fibrillation Treated with Warfarin, Dabigatran, or Rivaroxaban Blake Charlton MD1, Gboyega.

Characterisation of Myocardial Injury via T1 Mapping in Early Reperfused Myocardial Infarction and its Relationship with Global and Regional Diastolic.

Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated with Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation.

A Randomised Controlled Trial on the Effect of Nurse-Led Educational Intervention at the Time of Catheter Ablation for Atrial Fibrillation on Quality.

Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Non-valvular Atrial Fibrillation.

Volume 149, Issue 6, Pages (June 2016)

Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared With Warfarin Among Long-term Anticoagulated.

Procedure-specific Cardiac Surgeon Volume associated with Patient outcome following Valve Surgery, but not Isolated CABG Surgery Stephanie L. Ch’ng,

When should aspirin be dropped from triple therapy?

How Do We Incorporate Patient Perspectives Into Clinical Trial Design?

An approach to using risk scores for stroke and bleeding in clinical practice. An approach to using risk scores for stroke and bleeding in clinical practice.

David R. Holmes, Jr., M.D. Mayo Clinic, Rochester

Symptom-to-Balloon Time is a Strong Predictor of Adverse Events Following Primary Percutaneous Coronary Intervention: Results From the Australian Capital.

Heart, Lung and Circulation

American Heart Journal

Volume 28, Issue 6, Pages (December 2012)

Frontiers of anticoagulation therapy for atrial fibrillation

Differences and trends in stroke prevention anticoagulation in primary care vs cardiology specialty management of new atrial fibrillation: The Retrospective.

Anticoagulation in Atrial Fibrillation

Management of atrial fibrillation. Patterns of Atrial Fibrillation.

Russell D. Hull, MBBS, MSc, Graham F. Pineo, MD, Rollin F

Covering the Bases in Cardioversion

Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation by Surbhi Shah, Faye L. Norby, Yvonne.

Renato D. Lopes, MD, PhD, Li Li, MS, Christopher B

Nat. Rev. Cardiol. doi: /nrcardio

Volume 15, Issue 1, Pages (January 2018)

Advances in Coronary Artery Disease: Moving Beyond Antiplatelet Therapy.

Educational Event 23rd & 24th January 2013

Selecting NOACs for High-Risk Patients

Timing the First Postoperative Dose of Anticoagulants

CHA2DS2-VASc Score Is Directly Associated with the Risk of Pulmonary Embolism in Patients with Atrial Fibrillation Walid Saliba, MD, MPH, Gad Rennert,

Adherence in SPAF: Measures to Improve Care

Left atrial appendage closure: A new technique for clinical practice

Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Phase III Atrial Fibrillation Trials Giulia Renda, MD, PhD, Marta.

Timing the First Postoperative Dose of Anticoagulants

Risk of Gastrointestinal Bleeding in Patients Taking Non–Vitamin K Antagonist Oral Anticoagulants: A Systematic Review and Meta-analysis Corey S. Miller,

SAMe-TT2R2 Score, Time in Therapeutic Range, and Outcomes in Anticoagulated Patients with Atrial Fibrillation Pilar Gallego, MD, PhD, Vanessa Roldán,

Alexander M. Walker, MD, DrPH, Dimitri Bennett, MD, MPH Heart Rhythm

Alexander M. Walker, MD, DrPH, Dimitri Bennett, MD, MPH Heart Rhythm

Russell D. Hull, MBBS, MSc, Graham F. Pineo, MD, Rollin F

Cancer-Associated Thrombosis

Are Atrial Fibrillation Patients Receiving Warfarin in Accordance with Stroke Risk? Peter J. Zimetbaum, MD, Amit Thosani, MD, Hsing-Ting Yu, MPH, Yan.

Truman J. Milling, MD, Alex C. Spyropoulos, MD

Evaluation of the HAS-BLED, ATRIA, and ORBIT Bleeding Risk Scores in Patients with Atrial Fibrillation Taking Warfarin Keitaro Senoo, MD, Marco Proietti,

2014 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation Atul Verma, MD, John A. Cairns, MD, L.

Management of Major Bleeding Events in Patients Treated With Dabigatran for Nonvalvular Atrial Fibrillation: A Retrospective, Multicenter Review Truman.

Isla M. Ogilvie, PhD, Nick Newton, PhD, Sharon A

Which NOAC and When for Stroke Prevention in AF?

2018 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation Jason G. Andrade, MD, Atul Verma, MD,

Subtle Cognitive Dysfunction in Resolving High Altitude Cerebral Edema Revealed by a Clock Drawing Test Ian Quigley, MBBS, Ken Zafren, MD Wilderness.

Volume 14, Issue 12, Pages (December 2017)

Termination of anticoagulation therapy at 45 days after concomitant atrial fibrillation catheter ablation and left atrial appendage occlusion resulting.

Anticoagulation with apixaban in a patient with a left ventricular assist device and gastrointestinal bleeding: A viable alternative to warfarin? Francesco.

Volume 10, Issue 9, Pages (September 2013)

The American Journal of Medicine

Unusual severe hemodynamic failure associated with standard dose of intravenous flecainide for pharmacological cardioversion of atrial fibrillation Aref.

Left Atrial Appendage Occlusion for The Unmet Clinical Needs of Stroke Prevention in Nonvalvular Atrial Fibrillation David R. Holmes, MD, Mohamad Alkhouli,

Erratum Canadian Journal of Cardiology

SAFETY AND EFFICACY OF DABIGATRAN COMPARED TO BRIDGED WARFARIN FOR PERIPROCEDURAL ANTICOAGULATION IN PATIENTS UNDERGOING RADIOFREQUENCY ABLATION FOR.

Figure 8. Stroke prevention strategy in patients with AF

Gianluigi Savarese et al. JCHF 2016;4:

Presentation transcript:

Heart, Lung and Circulation Novel Oral Anticoagulants in Direct Current Cardioversion for Atrial Fibrillation Giuseppe Femia, BSc (Hons), MBBS (Hons), Taufik Fetahovic, MBBS, FRACP, Pratap Shetty, MBBS, MD, FRACP, FCSANZ, Astin Lee, MBBS (Hons), FRCP, FRACP, FCSANZ Heart, Lung and Circulation DOI: 10.1016/j.hlc.2017.06.726 Copyright © 2017 Terms and Conditions

Figure 1 Utilisation trends of warfarin, apixaban, dabigatran and rivaroxaban from January 2014 to June 2016. Heart, Lung and Circulation DOI: (10.1016/j.hlc.2017.06.726) Copyright © 2017 Terms and Conditions

Figure 2 Utilisation of warfarin and Novel Oral Anticoagulants in relation to CHADSVASc score. Heart, Lung and Circulation DOI: (10.1016/j.hlc.2017.06.726) Copyright © 2017 Terms and Conditions

Figure 3 Incidence of Cerebral Vascular Accidents and Major Bleeding Events in Patients Treated with Warfarin and Novel Oral Anticoagulants (NOACs). Heart, Lung and Circulation DOI: (10.1016/j.hlc.2017.06.726) Copyright © 2017 Terms and Conditions

Figure 4 Incidence of Cerebral Vascular Accidents and Major Bleeding Events in Patients Treated with Short Duration (<5 days) or Long Duration (>5 days) Novel Oral Anticoagulant (NOAC) Therapy. Heart, Lung and Circulation DOI: (10.1016/j.hlc.2017.06.726) Copyright © 2017 Terms and Conditions